Patents Assigned to AROG Pharmaceuticals, LLC
  • Method of inhibiting constitutively active phosphorylated FLT3 kinase
    Patent number: 9023880
    Abstract: The present invention includes a method of inhibiting or reducing deregulated FLT3 tyrosine kinase activity or FLT3 tyrosine kinase expression in a subject with a proliferative disease by administering to the subject having or suspected to have the proliferative disease, a therapeutically or prophylactically effective amount of the compound of Formula I: or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: May 5, 2015
    Assignee: AROG Pharmaceuticals, LLC
    Inventor: Vinay K. Jain
  • Method of Inhibiting Constitutively Active Phosphorylated FLT3 Kinase
    Publication number: 20140088143
    Abstract: The present invention includes a method of inhibiting or reducing deregulated FLT3 tyrosine kinase activity or FLT3 tyrosine kinase expression in a subject with a proliferative disease by administering to the subject having or suspected to have the proliferative disease, a therapeutically or prophylactically effective amount of the compound of Formula I: or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 13, 2013
    Publication date: March 27, 2014
    Applicant: AROG Pharmaceuticals, LLC
    Inventor: Vinay K. Jain
  • METHOD OF INHIBITING MUTANT C-KIT
    Publication number: 20140088147
    Abstract: The present invention includes a method of reducing or inhibiting the kinase activity of C-KIT mutant tyrosine kinase activity in a cell or a subject, and the use of such compound for treating mutant C-KIT driven cell proliferative disorder(s) in a subject related to using a compound of the present invention: or pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 13, 2013
    Publication date: March 27, 2014
    Applicant: AROG Pharmaceuticals, LLC
    Inventor: Vinay K. Jain